eFFECTOR Therapeutics, Inc., a biopharmaceutical company based in Foxboro, Massachusetts, has filed a post-effective amendment with the Securities and Exchange Commission (SEC) on July 30, 2024, to deregister all unsold securities previously registered under two Registration Statements. The affected Registration Statements are No. 333-259751, initially filed on September 23, 2021, and subsequently amended, and No. 333-262339, filed on January 25, 2022. This move is in accordance with the company's previous undertakings to remove from registration any securities that remain unsold at the end of the offering. The deregistration indicates that eFFECTOR Therapeutics, which is classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company, will not be proceeding with the sale of these securities to the public as initially planned.

eFFECTOR Therapeutics, Inc., a biopharmaceutical company based in Foxboro, Massachusetts, has filed a post-effective amendment with the Securities and Exchange Commission (SEC) on July 30, 2024, to deregister all unsold securities previously registered under two Registration Statements. The affected Registration Statements are No. 333-259751, initially filed on September 23, 2021, and subsequently amended, and No. 333-262339, filed on January 25, 2022. This move is in accordance with the company's previous undertakings to remove from registration any securities that remain unsold at the end of the offering. The deregistration indicates that eFFECTOR Therapeutics, which is classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company, will not be proceeding with the sale of these securities to the public as initially planned.